Autism Feedback To FDA: Focus On Communication, Redefine 'Irritability'
Executive Summary
US FDA’s 22nd Patient-Focused Drug Development meeting focused on the challenging disease of autism. It also showed how far FDA has come in embracing the patient-input process over the past five years.